Clinical Documentation Standards for Ketamine Treatment
Comprehensive clinical documentation is the backbone of quality ketamine therapy. Proper documentation serves multiple critical functions: supporting continuity of care, demonstrating medical necessity, enabling outcome tracking, meeting regulatory requirements, and providing legal protection. This guide establishes documentation standards that every ketamine practice should implement.
The Importance of Documentation
Why Documentation Matters
| Purpose | Significance | |---------|--------------| | Patient safety | Communication among providers; continuity of care | | Quality improvement | Track outcomes; identify areas for improvement | | Legal protection | Defense in malpractice claims; demonstrate standard of care | | Regulatory compliance | DEA, state medical board, HIPAA requirements | | Billing/reimbursement | Support medical necessity; justify charges | | Research/audit | Generate data for outcomes research; accreditation |
Documentation Principles
FACT: Documentation should be:
- Factual: Objective observations, not opinions or judgments
- Accurate: Precise, truthful, without exaggeration
- Complete: All relevant information included
- Timely: Documented contemporaneously or as soon as possible
Additional Principles:
- Patient-centered: Focus on patient's presentation and response
- Legible: Readable by all who need access
- Standardized: Consistent format enables efficient review
- Signed and dated: Clear attribution and timing
Initial Evaluation Documentation
Comprehensive Psychiatric Evaluation
Required Components:
Identifying Information
Patient Name:
Date of Birth:
Medical Record Number:
Date of Evaluation:
Evaluating Provider:
Referral Source:
Chief Complaint
Document in patient's own words why they are seeking treatment.
Example: "Patient reports: 'I've tried everything for my depression and nothing works. I heard ketamine might help.'"
History of Present Illness (HPI)
Required Elements:
| Element | Documentation | |---------|---------------| | Current symptoms | Specific depressive/anxiety symptoms | | Onset | When current episode began | | Duration | How long symptoms have been present | | Severity | Impact on functioning; severity ratings | | Course | Worsening, stable, fluctuating | | Precipitants | Triggers or contributing factors | | Associated symptoms | Sleep, appetite, concentration, energy | | Suicidal ideation | Current and recent suicidal thoughts/behaviors |
Example: "45-year-old female presenting with treatment-resistant major depressive disorder. Current depressive episode began approximately 18 months ago following job loss. Symptoms have been persistent and gradually worsening despite multiple treatment trials. Current symptoms include depressed mood most of the day nearly every day, anhedonia (previously enjoyed gardening and reading), initial insomnia with early morning awakening, decreased appetite with 15-pound weight loss over 6 months, fatigue, difficulty concentrating affecting job performance, feelings of worthlessness and guilt, and passive suicidal ideation ('sometimes I think everyone would be better off without me') without current plan or intent. Patient denies active suicidal intent, access to means, or prior suicide attempts. PHQ-9 score today: 22 (severe). GAD-7 score: 14 (moderate anxiety)."
Psychiatric History
Required Elements:
| Element | Documentation | |---------|---------------| | Previous episodes | Number, timing, duration, severity | | Hospitalizations | Dates, reasons, duration, facilities | | Suicide attempts | Details, means, medical treatment | | Prior diagnoses | Including revisions | | Previous treatments | Medications, therapy, other |
Medication History Documentation:
Create a comprehensive table of past psychiatric medications:
| Medication | Max Dose | Duration | Response | Reason Stopped | |------------|----------|----------|----------|----------------| | Sertraline | 200 mg | 8 weeks | Minimal | Ineffective | | Bupropion | 450 mg | 12 weeks | Partial | Added to next | | Venlafaxine | 225 mg | 10 weeks | Minimal | Ineffective | | Lithium augmentation | 900 mg | 6 weeks | None | Ineffective |
Documentation of Treatment Resistance:
Specifically document criteria for treatment-resistant depression:
- Number of adequate antidepressant trials (≥2 required)
- Documentation of adequate dose and duration for each
- Assessment of adherence
- Nature of response (none, partial, initial then loss)
Example: "Treatment history documents failure of five adequate antidepressant trials from different classes over the past 18 months: sertraline (SSRI), venlafaxine (SNRI), bupropion (NDRI), mirtazapine (NaSSA), and lithium augmentation. All trials were at adequate doses for adequate duration (minimum 6 weeks at therapeutic dose). Patient reports good adherence, confirmed by pharmacy records. This meets criteria for treatment-resistant depression (Stage II by Thase-Rush staging)."
Medical History
Required Documentation:
- Chronic medical conditions
- Relevant acute conditions
- Surgical history
- Allergies (drug, environmental, food)
- Current medications (complete list)
- Review of systems
Specific Focus Areas for Ketamine:
| System | Specific Concerns | |--------|-------------------| | Cardiovascular | Hypertension, CAD, arrhythmia, CHF | | Hepatic | Liver disease, hepatitis | | Neurological | Seizure history, ICP elevation risk | | Respiratory | Sleep apnea, COPD | | Substance use | Current/past use, especially ketamine/PCP | | Endocrine | Thyroid disease, uncontrolled diabetes | | Genitourinary | Bladder conditions |
Social History
Document:
- Living situation
- Employment/disability status
- Relationships/support system
- Education level
- Substance use (alcohol, tobacco, illicit substances)
- Legal issues
- Functional status
Family History
- Psychiatric diagnoses in first-degree relatives
- Substance use disorders
- Suicide/suicide attempts
- Treatment responses in relatives
Mental Status Examination (MSE)
Complete MSE Required:
| Category | Elements to Document | |----------|---------------------| | Appearance | Grooming, attire, psychomotor activity | | Behavior | Cooperation, eye contact, movements | | Speech | Rate, rhythm, volume, tone | | Mood | Patient's reported mood (quote) | | Affect | Observed emotional expression, range, congruence | | Thought process | Linear, circumstantial, tangential, etc. | | Thought content | SI/HI, delusions, obsessions, phobias | | Perceptions | Hallucinations, illusions | | Cognition | Orientation, attention, memory, calculation | | Insight | Understanding of illness | | Judgment | Decision-making capacity |
Example: "MSE: Patient is a well-groomed female appearing stated age, in no acute distress. Cooperative with interview, fair eye contact. Speech normal rate and volume, somewhat monotone. Mood reported as 'hopeless.' Affect restricted in range, congruent with stated mood, tearful at times. Thought process linear and goal-directed. Thought content notable for passive suicidal ideation without plan or intent, feelings of worthlessness; no delusions. Denies auditory or visual hallucinations. Alert and oriented ×4. Attention intact to interview. Memory grossly intact. Insight fair (recognizes illness). Judgment intact (seeking appropriate treatment)."
Assessment
Required Elements:
- DSM-5 diagnosis(es) with specifiers
- Severity assessment
- Functional impact
- Risk assessment
Example: "1. Major depressive disorder, recurrent episode, severe, without psychotic features (F33.2)
- Treatment-resistant (Stage II)
- PHQ-9: 22 (severe)
- Significant functional impairment (unable to work)
- Generalized anxiety disorder (F41.1)
- GAD-7: 14 (moderate)
- Rule out persistent depressive disorder vs. MDD superimposed on dysthymia
Risk assessment: Moderate suicide risk based on passive suicidal ideation, severe depression, and hopelessness. Mitigating factors include denial of intent/plan, no prior attempts, intact social support. Safety plan in place."
Treatment Plan
Required Elements:
- Rationale for ketamine treatment
- Specific protocol (route, dose, frequency)
- Concurrent treatments (medications, therapy)
- Monitoring plan
- Follow-up schedule
- Safety planning
Example: "Treatment Plan:
- Initiate IV ketamine treatment for treatment-resistant depression
- Protocol: 0.5 mg/kg IV over 40 minutes
- Frequency: Twice weekly × 3 weeks (6 treatments)
- Setting: Office-based with continuous monitoring
- Continue current medications: venlafaxine 225 mg daily
- Continue weekly psychotherapy with Dr. Smith
- Monitoring: PHQ-9 at each visit, vital signs per protocol
- Follow-up: Reassess after treatment #3 and #6
- Safety plan reviewed and updated; patient agrees to contact crisis line or present to ED if suicidal thoughts intensify
Treatment rationale documented. Informed consent obtained. Patient verbalized understanding and agreement with plan."
Medical Clearance Documentation
Required Elements:
| Component | Documentation | |-----------|---------------| | History and physical | Complete H&P or relevant updates | | Vital signs | Baseline BP, HR, weight | | Laboratory results | CBC, CMP, TSH, UDS, pregnancy test | | ECG | If cardiovascular risk factors present | | Contraindication screening | Documented review of all contraindications | | Risk assessment | Medical risk assessment for ketamine | | Clearance statement | Provider statement of medical clearance |
Clearance Documentation Example: "Medical Clearance for Ketamine Treatment:
Medical history reviewed. No uncontrolled hypertension, cardiac disease, hepatic failure, or other absolute contraindications identified. Blood pressure today 128/82, within acceptable range. Laboratory review: CBC, CMP, TSH within normal limits. Urine drug screen negative. Pregnancy test negative.
Patient is medically cleared for IV ketamine treatment as described in treatment plan. Will monitor blood pressure and heart rate per protocol during treatments."
Informed Consent Documentation
See dedicated article on Informed Consent
Documentation Requirements:
- Consent discussion occurred (date, duration, participants)
- Elements discussed (checklist or narrative)
- Patient's questions and answers given
- Assessment of understanding
- Signed consent form (reference in note)
- Copy provided to patient
Treatment Session Documentation
Pre-Treatment Documentation
Required Elements for Each Session:
KETAMINE TREATMENT NOTE
Date: __________
Session Number: _____ of planned _____
Pre-Treatment Assessment:
- Vital signs: BP _____ HR _____ SpO2 _____ Weight _____
- Mental status: ________________________________
- Current symptoms: PHQ-9 _____ GAD-7 _____ C-SSRS _____
- Interval history since last treatment: ________________
- New symptoms or concerns: ________________________
- Medication changes: ______________________________
- New medical issues: ______________________________
- Substance use since last visit: _____________________
- Contraindication screening: [ ] No new contraindications
- Fasting confirmed: [ ] Yes [ ] No
- Driver present/confirmed: [ ] Yes
- Consent verified: [ ] Current consent on file
Treatment Administration Documentation
Required Elements:
Treatment Administration:
- Route: [ ] IV [ ] IM [ ] IN [ ] SL
- Dose: _____ mg (_____ mg/kg based on weight _____ kg)
- Start time: _____
- End time: _____
- Total infusion duration: _____ minutes
- Medication lot number: _____ (if required)
IV-Specific:
- IV site: _____________________
- IV gauge: _____
- IV started by: _______________
Monitoring Record:
Time | BP | HR | SpO2 | RR | Notes
________|_________|_____|______|_____|_____________
________|_________|_____|______|_____|_____________
________|_________|_____|______|_____|_____________
________|_________|_____|______|_____|_____________
________|_________|_____|______|_____|_____________
________|_________|_____|______|_____|_____________
Peak dissociation rating (0-10): _____
Intra-Treatment Documentation
Document:
- Patient's subjective experience (brief)
- Behavioral observations
- Any concerning symptoms
- Interventions required
- Response to interventions
Example: "During infusion, patient was calm with eyes closed, listening to music. Reported moderate dissociation (6/10) peaking around 20-minute mark. Brief period of tearfulness at 25 minutes; patient declined intervention, stated 'these are healing tears.' No nausea or distressing symptoms. Blood pressure peaked at 142/88 at 15 minutes, returned to baseline by end of infusion."
Adverse Events Documentation
If Adverse Events Occur:
Adverse Event Documentation:
- Event: __________________________________
- Time of onset: _____
- Severity: [ ] Mild [ ] Moderate [ ] Severe
- Duration: _____
- Vital signs at event: BP _____ HR _____ SpO2 _____
- Intervention(s): ____________________________
- Response to intervention: ____________________
- Outcome: _________________________________
- Follow-up required: [ ] Yes [ ] No
- Details: __________________________________
Post-Treatment Documentation
Required Elements:
Post-Treatment Assessment:
- Vital signs (discharge): BP _____ HR _____ SpO2 _____
- Mental status: _________________________________
- Dissociation resolved: [ ] Yes [ ] No
- Ambulation: [ ] Independent [ ] Assisted
- Orientation: [ ] Fully oriented [ ] Partial (specify)
- Discharge criteria met: [ ] Yes [ ] No
Discharge:
- Time of discharge: _____
- Discharge status: [ ] Good [ ] Fair [ ] Requires follow-up
- Discharged with: _____________________________
- Post-treatment instructions: [ ] Provided (verbal and written)
- Emergency contact information: [ ] Confirmed
- Next appointment: _____
Adverse events this session: [ ] None [ ] See adverse event documentation
Provider signature: _______________
Date/Time: _____________________
Comprehensive Session Note Example
KETAMINE TREATMENT NOTE
Patient: Jane Doe DOB: 01/15/1979 MRN: 12345
Date: 01/08/2026 Session: 3 of 6
PRE-TREATMENT:
Vital signs: BP 124/78, HR 72, SpO2 99%, Weight 68 kg
Mental status: Alert, cooperative, mildly anxious about treatment
PHQ-9: 18 (improved from baseline 22)
GAD-7: 12
C-SSRS: Passive ideation present but less frequent than prior visits
Interval history: Patient reports modest improvement in mood since last
treatment 3 days ago. Better sleep, slight improvement in appetite.
Continues to struggle with motivation and concentration.
Medications unchanged. No new medical issues. Denies alcohol/substance use.
Contraindication screen: No new contraindications identified.
Fasting confirmed: Yes (light meal 5 hours ago)
Driver present: Yes (husband in waiting room)
Consent: Current consent on file (dated 12/15/2025)
TREATMENT:
Route: IV
Dose: 34 mg (0.5 mg/kg)
Start time: 14:00
End time: 14:40
Duration: 40 minutes
IV site: Left antecubital, 22 gauge, started by RN Jones
Monitoring:
Time | BP | HR | SpO2 | RR | Notes
14:00 | 124/78 | 72 | 99% | 14 | Baseline
14:15 | 138/84 | 78 | 99% | 12 | Dissociation onset
14:25 | 142/86 | 82 | 99% | 12 | Peak dissociation (7/10)
14:40 | 134/82 | 76 | 99% | 14 | End of infusion
14:55 | 128/80 | 74 | 99% | 14 | Recovery
15:10 | 126/78 | 72 | 99% | 14 | Pre-discharge
Peak dissociation: 7/10
Patient experience: Patient tolerated treatment well. Reported "floaty"
sensation and visual distortions at peak. No distressing content.
Described experience as "peaceful" overall. No nausea or vomiting.
POST-TREATMENT:
Vital signs (15:15): BP 124/76, HR 70, SpO2 99%
Mental status: Alert, oriented ×4, pleasant affect, no acute distress
Dissociation resolved: Yes
Ambulation: Independent without difficulty
Discharge criteria: Met
DISCHARGE:
Time: 15:20
Status: Good
Discharged with: Husband
Post-treatment instructions: Provided (verbal and written)
Next appointment: 01/11/2026 (session 4)
ADVERSE EVENTS: None
CLINICAL IMPRESSION:
Patient continuing to show gradual improvement after third ketamine
treatment. PHQ-9 improved from 22 to 18. Treatment well tolerated.
Will continue protocol as planned.
PLAN:
1. Continue ketamine series as planned (sessions 4-6)
2. Continue venlafaxine 225 mg daily
3. Continue psychotherapy
4. Reassess response after session 6 to determine maintenance plan
_________________________
Dr. John Smith, MD
01/08/2026, 15:25
Outcome Tracking Documentation
Standardized Outcome Measures
Recommended Tracking Schedule:
| Measure | Timing | |---------|--------| | PHQ-9 | Each treatment session | | GAD-7 | Each treatment session | | C-SSRS | Each treatment session | | CGI-S/CGI-I | Each treatment and end of series | | Functional assessment | Baseline, mid-series, end of series | | Quality of life | Baseline and end of series |
Outcome Documentation Template
OUTCOME TRACKING - KETAMINE TREATMENT SERIES
Patient: _______________ Series dates: _____ to _____
Baseline Assessment (Date: _____):
- PHQ-9: _____ GAD-7: _____ C-SSRS: _____
- CGI-S: _____
- Functional status: _______________________________
- Employment status: [ ] Working [ ] Disabled [ ] Other
Treatment Sessions:
Session | Date | PHQ-9 | GAD-7 | C-SSRS | Notes
1 | | | | |
2 | | | | |
3 | | | | |
4 | | | | |
5 | | | | |
6 | | | | |
End of Series Assessment (Date: _____):
- PHQ-9: _____ GAD-7: _____ C-SSRS: _____
- CGI-I: _____
- Response: [ ] Responder (≥50% reduction) [ ] Non-responder
- Remission: [ ] Yes (PHQ-9 <5) [ ] No
- Functional change: ________________________________
Treatment Summary:
- Total treatments completed: _____ of _____ planned
- Adverse events: _________________________________
- Protocol modifications: ___________________________
- Patient subjective response: ______________________
Maintenance Plan: _________________________________
Response Definitions
Document using standardized definitions:
| Outcome | Definition | |---------|------------| | Response | ≥50% reduction in depression score | | Partial response | 25-49% reduction in depression score | | Non-response | <25% reduction in depression score | | Remission | PHQ-9 <5 or MADRS <10 | | Relapse | Return to baseline severity after response/remission |
Billing Documentation Requirements
Medical Necessity Documentation
Required Elements for Billing:
| Element | Documentation | |---------|---------------| | Diagnosis | ICD-10 code with documentation supporting diagnosis | | Treatment resistance | Documentation of failed prior treatments | | Appropriateness | Why ketamine is indicated for this patient | | Medical clearance | Patient is appropriate candidate | | Treatment plan | Specific protocol with rationale |
CPT Code Documentation Requirements
For IV Infusion (96365, 96366):
| Requirement | Documentation | |-------------|---------------| | Start/stop times | Exact times documented | | Total duration | Minutes of infusion | | Drug administered | Name, dose, route | | Direct supervision | Qualifying provider available | | Medical necessity | Documented in note |
For IM Injection (96372):
| Requirement | Documentation | |-------------|---------------| | Drug administered | Name, dose, route | | Site of injection | Documented | | Provider | Who administered | | Medical necessity | Documented |
For E&M Services (99213-99215):
| Level | Documentation Requirements | |-------|---------------------------| | 99213 | Low complexity MDM or 20-29 min total time | | 99214 | Moderate complexity MDM or 30-39 min total time | | 99215 | High complexity MDM or 40-54 min total time |
Superbill Documentation
For self-pay patients seeking out-of-network reimbursement:
SUPERBILL FOR KETAMINE TREATMENT
Provider Information:
Name: _____________________
NPI: _____________________
Tax ID: ___________________
Address: __________________
Patient Information:
Name: ____________________
DOB: _____________________
Date of Service: ___________
Diagnosis Codes:
[ ] F33.2 - MDD, recurrent, severe
[ ] F33.1 - MDD, recurrent, moderate
[ ] F32.2 - MDD, single episode, severe
[ ] F41.1 - Generalized anxiety disorder
[ ] Other: _______________
Procedure Codes:
[ ] 96365 - IV infusion, initial hour $_____
[ ] 96366 - IV infusion, additional hour $_____
[ ] 96372 - Therapeutic injection $_____
[ ] 99213 - Office visit, level 3 $_____
[ ] 99214 - Office visit, level 4 $_____
[ ] 99215 - Office visit, level 5 $_____
[ ] J3490 - Ketamine, per dose $_____
Total Charges: $_____
Amount Paid: $_____
Provider Signature: _______________
Date: _______________
Documentation Storage and Retention
Retention Requirements
| Record Type | Minimum Retention | |-------------|-------------------| | Adult patient records | 7-10 years (varies by state) | | Minor patient records | Until age 18 + 7 years | | Controlled substance records | 2 years (DEA minimum) | | Billing records | 7 years | | Consent forms | Duration of treatment + retention period |
Security Requirements
HIPAA-Compliant Storage:
- Encrypted electronic records
- Password-protected access
- Audit trails for record access
- Secure backup procedures
- Physical security for paper records
Controlled Substance Record Keeping
DEA Requirements:
| Record | Requirement | |--------|-------------| | Inventory | Initial and biennial inventories | | Acquisition | Records of each purchase | | Administration | Log of each dose administered | | Disposal | Witnessed disposal documentation | | Loss/theft | DEA Form 106 |
Administration Log Template:
KETAMINE ADMINISTRATION LOG
Date: __________ Page: _____ of _____
Date | Time | Patient | Dose (mg) | Route | Lot # | Provider | Witness
_____|______|_________|___________|_______|_______|__________|________
_____|______|_________|___________|_______|_______|__________|________
_____|______|_________|___________|_______|_______|__________|________
Running inventory:
Starting quantity: _____ mg/mL vials: _____
Ending quantity: _____ mg/mL vials: _____
Discrepancy: [ ] None [ ] See explanation: _______________
Provider signature: _______________ Date: _______
Quality Assurance for Documentation
Documentation Audit Checklist
Monthly Audit Sample (10% of charts):
DOCUMENTATION AUDIT FORM
Chart: _______________ Date of service: _______
Auditor: ______________ Audit date: __________
Initial Evaluation:
[ ] Complete H&P
[ ] Treatment history documented
[ ] Treatment resistance criteria documented
[ ] Diagnosis with DSM-5 criteria
[ ] Risk assessment
[ ] Treatment plan with rationale
[ ] Informed consent documented
Treatment Sessions:
[ ] Pre-treatment assessment complete
[ ] Vital signs documented per protocol
[ ] Dose and route documented
[ ] Start/stop times recorded
[ ] Monitoring record complete
[ ] Post-treatment assessment complete
[ ] Discharge criteria documented
[ ] Adverse events documented (if applicable)
Outcome Tracking:
[ ] Standardized measures at each visit
[ ] Response/remission documented
[ ] Treatment summary at end of series
Billing Documentation:
[ ] Medical necessity clear
[ ] Time documentation supports coding
[ ] Diagnosis codes appropriate
Overall Assessment:
[ ] Meets standards
[ ] Deficiencies identified (list below)
Deficiencies: _________________________________
Corrective action: ____________________________
Follow-up date: ______________________________
Common Documentation Deficiencies
| Deficiency | Correction | |------------|------------| | Missing vital signs | Ensure all required timepoints documented | | Incomplete treatment history | Detailed medication history required | | Unclear medical necessity | Explicitly document why ketamine is indicated | | Missing times | Document exact start/stop times | | No outcome measures | Use standardized instruments at each visit | | Incomplete consent documentation | Document discussion, not just signature | | Missing adverse event details | Complete adverse event form for any event |
Clinical Takeaways
-
Document Thoroughly at Intake: Comprehensive initial evaluation documentation establishes medical necessity, demonstrates appropriate patient selection, and provides baseline for outcome tracking.
-
Standardize Treatment Documentation: Use templates and checklists to ensure every treatment session is documented consistently and completely.
-
Track Outcomes Systematically: Use validated instruments at every visit. This data demonstrates efficacy, guides clinical decisions, and supports quality improvement.
-
Support Billing with Documentation: Medical necessity, time documentation, and appropriate coding all depend on thorough clinical documentation.
-
Meet Controlled Substance Requirements: DEA requirements for controlled substance documentation are specific and non-negotiable. Maintain meticulous inventory and administration logs.
-
Audit Regularly: Regular documentation audits identify deficiencies before they become problems. Create a culture of documentation excellence.
-
Retain Records Appropriately: Know your state's retention requirements and maintain secure, compliant record storage.
-
Document in Real Time: Contemporaneous documentation is more accurate and more defensible than retrospective documentation. Document during or immediately after each encounter.
Excellent documentation is a hallmark of quality clinical care. While documentation requirements may seem burdensome, they ultimately serve patients through enhanced safety, continuity, and accountability. Invest in documentation systems and training to make thorough documentation efficient and routine.
References
- Centers for Medicare & Medicaid Services. Documentation Guidelines for Evaluation and Management Services. CMS. 2021.
- Drug Enforcement Administration. Practitioner's Manual. DEA. 2020.
- American Medical Association. CPT Professional Edition. AMA. 2024.
- HIPAA Journal. HIPAA Medical Records Retention Requirements. 2023.
- Joint Commission. Medical Record Documentation Standards. Joint Commission. 2024.
